Literature DB >> 12124773

Structure-activity relationships of heparin-mimicking compounds in induction of bFGF release from extracellular matrix and inhibition of smooth muscle cell proliferation and heparanase activity.

Miriam Benezra1, Rivka Ishai-Michaeli, Shmuel A Ben-Sasson, Israel Vlodavsky.   

Abstract

A series of nine synthetic polyaromatic compounds were synthesized by polymerization of aromatic ring monomers with formaldehyde, which yield substantially ordered backbones with different functional anionic groups (hydroxyl and carboxyl) on the phenol ring. These compounds were tested for their heparin-mimicking activity: (1) inhibition of heparanase activity; (2) inhibition of SMC proliferation; and (3) release of bFGF from the ECM. We demonstrate that compounds that have two hydroxyl groups para and ortho to the carboxylic group and a carboxylic group at a distance of two carbons from the phenol ring inhibit heparanase activity and SMC proliferation, as well as induced an almost complete release of bFGF from ECM. Addition of a methyl group next to the carboxylic group led to a preferential inhibition of heparanase activity. Similar results were obtained with a compound that contains one hydroxyl group para to the carboxylic group and an ether group near the carboxylic group on the phenol ring. Preferential inhibition of SMC proliferation was best achieved when the position of the hydroxyl group is para and ortho to the carboxylic group and the carboxylic group is at a distance of one carbon from the phenol ring. On the other hand, for maximal release of bFGF from ECM, the position of the carboxylic group should be three carbons away from the phenol ring. These new heparin-mimicking compounds may have a potential use in inhibition of tumor metastasis, arteriosclerosis, and inflammation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124773     DOI: 10.1002/jcp.10136

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Inhibitors of slit protein interactions with the heparan sulphate proteoglycan glypican-1: potential agents for the treatment of spinal cord injury.

Authors:  Elizabeth Lau; Richard U Margolis
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-10-16       Impact factor: 2.557

2.  Poly(vinyl sulfonate) Facilitates bFGF-Induced Cell Proliferation.

Authors:  Thi H Nguyen; Samantha J Paluck; Andrew J McGahran; Heather D Maynard
Journal:  Biomacromolecules       Date:  2015-08-17       Impact factor: 6.988

3.  YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor.

Authors:  Dafna Bonneh-Barkay; Stephanie J Bissel; Gouji Wang; Kenneth N Fish; Georgina C B Nicholl; Samuel W Darko; Rafael Medina-Flores; Michael Murphey-Corb; Premeela A Rajakumar; Julia Nyaundi; John W Mellors; Robert Bowser; Clayton A Wiley
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

4.  A Heparin-Mimicking Block Copolymer Both Stabilizes and Increases the Activity of Fibroblast Growth Factor 2 (FGF2).

Authors:  Samantha J Paluck; Thi H Nguyen; Jonghan P Lee; Heather D Maynard
Journal:  Biomacromolecules       Date:  2016-09-13       Impact factor: 6.988

Review 5.  Heparin-Mimicking Polymers: Synthesis and Biological Applications.

Authors:  Samantha J Paluck; Thi H Nguyen; Heather D Maynard
Journal:  Biomacromolecules       Date:  2016-10-14       Impact factor: 6.988

6.  The Antitumor Effect of Gekko Sulfated Glycopeptide by Inhibiting bFGF-Induced Lymphangiogenesis.

Authors:  Xiu-Li Ding; Ya-Nan Man; Jian Hao; Cui-Hong Zhu; Chang Liu; Xue Yang; Xiong-Zhi Wu
Journal:  Biomed Res Int       Date:  2016-04-12       Impact factor: 3.411

Review 7.  Glycosaminoglycan-Inspired Biomaterials for the Development of Bioactive Hydrogel Networks.

Authors:  Mariana I Neves; Marco Araújo; Lorenzo Moroni; Ricardo M P da Silva; Cristina C Barrias
Journal:  Molecules       Date:  2020-02-21       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.